Regenxbio Inc (RGNX)
21.05
-1.13
(-5.09%)
USD |
NASDAQ |
Mar 28, 16:00
21.05
0.00 (0.00%)
After-Hours: 17:01
Regenxbio SG&A Expense (Quarterly): 19.08M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 19.08M |
September 30, 2023 | 23.08M |
June 30, 2023 | 23.70M |
March 31, 2023 | 22.63M |
December 31, 2022 | 21.21M |
September 30, 2022 | 20.92M |
June 30, 2022 | 20.83M |
March 31, 2022 | 22.32M |
December 31, 2021 | 22.04M |
September 30, 2021 | 21.03M |
June 30, 2021 | 18.42M |
March 31, 2021 | 17.84M |
December 31, 2020 | 17.57M |
September 30, 2020 | 15.86M |
June 30, 2020 | 15.55M |
March 31, 2020 | 14.83M |
December 31, 2019 | 14.45M |
September 30, 2019 | 12.40M |
June 30, 2019 | 13.40M |
Date | Value |
---|---|
March 31, 2019 | 11.56M |
December 31, 2018 | 11.14M |
September 30, 2018 | 9.008M |
June 30, 2018 | 8.318M |
March 31, 2018 | 8.38M |
December 31, 2017 | 4.808M |
September 30, 2017 | 9.444M |
June 30, 2017 | 6.355M |
March 31, 2017 | 6.622M |
December 31, 2016 | 5.742M |
September 30, 2016 | 6.20M |
June 30, 2016 | 6.169M |
March 31, 2016 | 5.479M |
December 31, 2015 | 4.241M |
September 30, 2015 | 2.567M |
June 30, 2015 | 3.397M |
March 31, 2015 | 1.716M |
December 31, 2014 | 1.119M |
September 30, 2014 | 1.07M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
11.56M
Minimum
Mar 2019
23.70M
Maximum
Jun 2023
18.44M
Average
18.75M
Median
SG&A Expense (Quarterly) Benchmarks
Sarepta Therapeutics Inc | 131.70M |
Amgen Inc | 2.274B |
Gilead Sciences Inc | 1.608B |
AbbVie Inc | 3.193B |
Bristol-Myers Squibb Co | 2.073B |